Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Other Non-Current Assets (2020 - 2024)

Universe Pharmaceuticals' Other Non-Current Assets history spans 4 years, with the latest figure at $96141.0 for Q1 2024.

  • On a quarterly basis, Other Non-Current Assets changed N/A to $96141.0 in Q1 2024 year-over-year; TTM through Mar 2024 was $96141.0, a N/A change, with the full-year FY2023 number at $35864.0, down 98.53% from a year prior.
  • Other Non-Current Assets hit $96141.0 in Q1 2024 for Universe Pharmaceuticals, up from $35864.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for UPC hit a ceiling of $443.7 billion in Q3 2020 and a floor of $35864.0 in Q3 2023.
  • Historically, Other Non-Current Assets has averaged $110.9 billion across 4 years, with a median of $1.3 million in 2022.
  • The widest YoY moves for Other Non-Current Assets: up 98.53% in 2023, down 98.53% in 2023.
  • Tracing UPC's Other Non-Current Assets over 4 years: stood at $443.7 billion in 2020, then crashed by 100.0% to $2.4 million in 2022, then tumbled by 98.53% to $35864.0 in 2023, then skyrocketed by 168.07% to $96141.0 in 2024.
  • Business Quant data shows Other Non-Current Assets for UPC at $96141.0 in Q1 2024, $35864.0 in Q3 2023, and $2.4 million in Q3 2022.